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Abstract
Background
Country-specific forecasts of the growing non-communicable disease (NCD) burden in age-
ing HIV-positive patients will be key to guide future HIV policies. We provided the first
national forecasts for Italy and the Unites States of America (USA) and quantified direct cost
of caring for these increasingly complex patients.
Methods and Setting
We adapted an individual-based model of ageing HIV-positive patients to Italy and the USA,
which followed patients on HIV-treatment as they aged and developed NCDs (chronic kid-
ney disease, diabetes, dyslipidaemia, hypertension, non-AIDS malignancies, myocardial
infarctions and strokes). The models were parameterised using data on 7,469 HIV-positive
patients from the Italian Cohort Naïve to Antiretrovirals Foundation Study and 3,748 com-
mercially-insured patients in the USA and extrapolated to national level using national sur-
veillance data.
Results
The model predicted that mean age of HIV-positive patients will increase from 46 to 59 in
Italy and from 49 to 58 in the USA in 2015–2035. The proportion of patients in Italy and the
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USA diagnosed with1 NCD is estimated to increase from 64% and 71% in 2015 to 89%
and 89% by 2035, respectively, driven by moderate cardiovascular disease (CVD) (hyper-
tension and dyslipidaemia), diabetes and malignancies in both countries. NCD treatment
costs as a proportion of total direct HIV costs will increase from 11% to 23% in Italy and from
40% to 56% in the USA in 2015–2035.
Conclusions
HIV patient profile in Italy and the USA is shifting to older patients diagnosed with multiple
co-morbidity. This will increase NCD treatment costs and require multi-disciplinary patient
management.
Introduction
Recent efforts to improve HIV care cascades have highlighted engagement levels in care glob-
ally and the challenges with starting and maintaining HIV-positive people on antiretroviral
therapy (ART) [1]. With effective ART and extended life expectancy [2] new challenges are
arising around the long-term management of patient relating to the increasing burden of non-
communicable diseases (NCDs) [3]. Although the pathophysiological mechanisms of NCDs in
the context of HIV are not fully understood, it likely involves complex interactions between
traditional risk factors, including smoking, diet, and exercise, and HIV-specific risk factors,
for example long-term immune activation and inflammation and toxicity related to long-term
ART use [3–8].
A recent model-based study provided the first insight into the clinical implications of an
ageing population in The Netherlands [9]. It showed that the mean age of HIV-positive
patients is expected to increase rapidly in the coming 15 years, accompanied by a sharp
increase in the burden of both NCDs and use of co-medication (in addition to ART). The
study highlighted the clinical implications of this disease shift, estimating that 40% of patients
will likely experience complications due to contra-indications or drug-interactions between
co-medication and recommended ART by 2030 [9]. Having robust national projections for
the nature and scale of NCD burden and likely economic implications for HIV care will help
inform national and regional guidelines regarding the screening, monitoring and treatment of
NCDs within HIV care.
In this study we adapted an individual-based model of the ageing HIV-positive population
on ART [9] to Italy and the United States of America (USA) by using real-world data to pro-
vide the first projections of the changing NCD burden and direct NCD treatment costs associ-
ated with treating these increasingly complex patients in those countries in the coming two
decades.
Materials and Method
Model
Two individual-based models of the ageing HIV-positive population were developed, one
for Italy and one for the USA, by adapting an existing model [9]. Fig 1 illustrates the basic
model structure, with full details of model design in the supplement (S1 File). Briefly, the
model followed the ageing Italian and US HIV-positive population on ART from 1st January
2010 to 31st December 2035, and probabilistically simulated clinical events (hypertension,
Non-communicable disease and care costs in HIV
PLOS ONE | https://doi.org/10.1371/journal.pone.0186638 October 23, 2017 2 / 12
Bristol-Meyers Squibb, Gilead, ViiV Health Care,
Merck Sharp Dohme, ABBvie, Janssen. FB has
received travel grants from Bristol-Myers Squibb.
TBH reports grants from Gilead Sciences, during
the conduct of the study; grants from BMGF, World
Bank, UNAIDS, Rush Foundation, Wellcome Trust,
personal fees from BMGF, New York University,
WHO, GFATM. ADAM reports personal fees from
Jannsen, Gilead Sciences, Merck Sharp Dohme,
Bristol-Myers Squibb and Abbive and funds paid to
institution by Gilead Sciences. EG reports personal
fees from Janssen, Otsuka Novel Products, Gilead
Sciences, Angeletti and funds paid to institution
from Gilead Sciences and Janssen. AS received
funds from ViiV, Gilead MSD, Abbvie, Jansen,
BMS. PH has received consultancy payments and
speaking fees from Gilead and Pfizer. This does not
alter our adherence to PLOS ONE policies on
sharing data and materials.
dyslipidaemia, chronic kidney disease (CKD), diabetes, ever being diagnosed with a non-AIDS
defining malignancies, ever having a stroke or myocardial infraction (MIs), and mortality).
We referred to hypertension and dyslipidaemia as ‘moderate’ cardiovascular disease (CVD)
and ever having a MI or stroke as ‘serious CVD’. NCD risk is based on patient’s age and sex,
and the propensity for one NCD to increase the risk of another NCD (Fig 1 dashed arrows),
e.g. for hypertension to increase CKD risk.
Each model was first constructed at ‘cohort’ level (limited to representing only the nation-
ally representative patient cohort for which data were available), in order to carry out-of-sam-
ple validation checks (against 2010 to 2015 data hold-outs) (Section 6 in S1 File). The model
was then extrapolated to national level assuming patterns observed in the cohorts were fully
representative of the national level, and by combining with national surveillance data on HIV
incidence, ART coverage and number of people on ART to scale the cohort of modelled
patients.
Demographic factors of HIV-positive patients on ART in 2010 (at the start of the model)
were assigned probabilistically using frequency distributions from the cohorts. Rates of entry
into care were based on estimated number of patients starting ART calculated using national
surveillance data (Section 4 in S1 File) and assuming a conservative medium HIV-incidence
scenario (i.e. a small and gradual reduction in HIV incidence up to 2035) and constant ART
coverage. Results for additional HIV incidence and ART coverage scenarios can be found in
the supplement (Section 7 in S1 File), including a scenario with constant HIV incidence, as
reported in recent years in Italy and USA [10–12]. Disease-specific mortality rates by age and
sex were taken from a large multi-cohort study, and adjusted for national mortality estimates
(Section 2 in S1 File).
Existing NCDs amongst patients in 2010 (at the start of the model) were modelled using
age-and-sex-specific prevalence estimates and new NCD events simulated using age-and-sex-
Fig 1. Basic schematic of the model design. The model follows patients on antiretroviral therapy from 2010 to 2035 or
death. The model simulates how patients age over time and develop clinical events, including non-communicable diseases
or death. The model takes into account key interactions between demographic factors (blue), e.g. how age and gender can
impact risk of death, and clinical factors (green) e.g how hypertension can increase the risk of chronic kidney disease or
death. Adapted from source: Smit et al [9]. Abbreviations: Myocardial Infarction (MI), Chronic Kidney Disease (CKD).
https://doi.org/10.1371/journal.pone.0186638.g001
Non-communicable disease and care costs in HIV
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specific incidence estimates per 1,000 person-years of follow-up from cohort data (Section 3 in
S1 File). Parameters describing the propensity for one NCD to increase the risk of another
NCD (Fig 1 dashed arrows) were taken from the existing model by Smit et al [9] (Section 3 in
S1 File). All NCDs were defined in accordance with clinical and laboratory guidelines for diag-
nosis [13] (Section 3 in S1 File).
The models were used to generate projections of age structure and NCD burden for each
country. All model results were based on the average of 100 model simulations.
Data
The models were parameterised using data from HIV clinical follow-up from the Italian
ICONA (Italian Cohort Naïve from Antiretrovirals) Foundation Study and from the Truven
MarketScan dataset of commercially (privately) insured patients’ claims data from the USA.
All patients aged18 years old, infected with HIV-1 only, who were ART-naïve prior to enter-
ing the cohort were included. Table 1 provides a basic description of the patients included in
the study.
The Italian model was parameterised using information from 7,469 HIV-positive patients
receiving care from 1997 onwards at one of the 42 infectious disease centres across the country
which contribute data to the ICONA, which was established in 1997 and whose design has
been described previously [14]. A baseline population of 2,774 patients who started ART from
1st January 1997 to 31st December 2009 were used to parameterise the model, and 4,695
patients on ART who were in care from 1st January 2010 to 31st December 2015 were used to
carry out out-of-sample validation.
The US model was developed using data on 3,748 commercially-insured HIV-positive
patients in the USA. The data reflected a retrospective analysis of commercially-insured HIV-
positive patients in the US who were drawn from a geographically representative national sam-
ple [15]. The model was parametrized using 2,268 HIV-positive individuals with record of pre-
scribed ART from 1st January 2005 to 31st December 2009, with 1,480 patients from 31st
December 2010 to 31st December 2014 to carry out out-of-sample validation.
Per capita direct treatment costs of HIV and NCDs were collated from insurance data in
the USA and from the Brescia Local Health Agency (Brescia, Italy) database which tracks all
services provides by the National Health Service [16]. Treatment was assumed to be lifelong
for all NCDs, except for MIs, strokes and malignancies, were treatment was assumed to last
one year. The method for cost collation for Italy has been described previously [16,17], and in
Table 1. Demographic characteristics of the ICONA cohort and cohort of commercially-insured US
HIV-positive patients in 2010 used for model parameterization. Abbreviations: Antiretroviral therapy
(ART); interquartile range (IQR); United States of America (USA).
Italy (n = 1,724) USA (n = 2,268)
Sex
Male 1253 (72.7%) 1,862 (82.1%)
Female 471 (27.3%) 406 (17.9%)
Age in 2010, years (mean) 43.89 44.4
Time on ART
<1 year 52 (3.0%) 154 (6.8%)
1–5 years 893 (51.8%) 958 (42.2%)
>5 years 779 (45.2%) 1156 (51.0%)
Median CD4 cells/mm3 count in 2010 (IQR) 501 (347, 699) 398 (273, 539)
https://doi.org/10.1371/journal.pone.0186638.t001
Non-communicable disease and care costs in HIV
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the USA comparing costs in HIV-positive patients with NCDs to matched HIV-positive
patients without NCDs (Section 5 in S1 File) [15].
Results
The model predicts that mean age of HIV-positive patients will increase from 46 to 59 in Italy
and from 49 to 58 in the USA (Fig 2) in 2015–2035. The proportion of patients50 years old
is predicted to increase from 30% and 39% in 2015 to 76% and 74% by 2035 and the propor-
tion65 years old from 5.5% to 29.3% and from 5.4% to 26.9% in Italy and the USA in 2015–
2035, respectively (Fig 2). Even if mean age of new patients remained at 2010 level, mean age
in 2035 would be 58 in Italy and 57 in the USA. If HIV incidence declines more rapidly or
slowly, mean age by 2035 is predicted to rise to 60 and 58 in Italy and 58 and 58 2in the USA,
respectively (Section 7 in S1 File).
In 2015, we find that the majority of patients in Italy and the USA were diagnosed with
either no NCDs (35% in Italy, 29% in the USA) or 1 NCD (42% in Italy, 37% in the US) (Fig
3A). The NCD burden is expected to increase over time, with a large proportion of patients
diagnosed with either 2 NCDs (31% in Italy, 25% in the US) or3 NCDs (29% in Italy, 44% in
the US) by 2035 (Fig 3A).
The increasing burden of NCDs will be driven by moderate CVD (hypertension, dyslipi-
daemia), diabetes and ever being diagnosed with a malignancy in both countries (Fig 3B). In
2015, moderate CVD contributes the greatest burden, affecting 60% and 61% of all HIV-posi-
tive patients on ART in Italy and the USA, respectively, followed by diabetes (9% and 12%
respectively) and malignancies (6% and 14%). The trend is expected to persist in 2035, with
the risk of being diagnosed with moderate CVD (affecting 85% of HIV-positive patients in
Italy and 84% in the USA), diabetes (affecting 27% of patients in Italy and 23% of patients in
the USA), or ever being diagnosed with a malignancy (affecting 16% of patients in Italy and
30% of patients in the USA) increasing.
When comparing the proportion of those with moderate (either dyslipidaemia or hyperten-
sion) and serious (ever having a MI or stroke) CVD in both countries, HIV-positive patients
in the USA are expected to have double the burden of serious CVD (Fig 3B) compared to Italy
by 2035 (21% in the USA versus 10% in Italy) with similar burdens of moderate CVD expected
in both populations.
Differences in the demographic shift and increase in NCD burden (faster in Italy compared
to the USA) appear to be driven by the differing HIV incidence. Higher HIV incidence in the
USA will likely resulting in a steady addition of new, young patients to care compared to Italy
where the existing population ages steadily and fewer new patients join care. Differences in
serious CVD between the two settings are driven by the higher age-specific prevalence and
incidence of serious CVD observed in the USA compared to Italy.
Annual direct NCD-related care costs are expected to increase between 2015 and 2035 in
both countries (Fig 4). In Italy, an estimated 11.1% of total HIV direct medical care costs are
associated with NCD treatment, and this is projected to increase to 22.8% by 2035 treatment.
The highest contribution to overall NCD treatment relate to dyslipidaemia (3.7% in 2015 and
5.1% in 2035) and CKD (3.6% in 2015 and 10.2% in 2035), with the greatest increase relating
to CKD. In the USA, direct NCD treatment costs account for 39.6% of total HIV care expendi-
ture in 2015 treatment, and is projected to increase to 55.7% by 2035 treatment. In dollar
terms, this would amount to the average cost per patient in the USA of $50,032 in 2015
($19,812 due to NCDs) and $68,270 in 2035 ($38,050 due to NCDs), assuming no discounting.
The highest contribution to overall direct NCD treatment costs are dyslipidaemia (13.3% in
Non-communicable disease and care costs in HIV
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2015 and 16.6% in 2035) and hypertension (12.9% in 2015 and 17.2% in 2035), and the greatest
increase relates to costs of CKD (5.8% of total care cost in 2015 to 12.0% in 2035).
Discussion
The ageing HIV-positive population in Italy and the USA will have major implications for
HIV care. Our forecasts suggest that three-quarters of HIV-positive patients on ART will be
Fig 2. The age distribution of HIV-positive patients on antiretroviral therapy in A. Italy and B. the USA
between 2015 and 2035.
https://doi.org/10.1371/journal.pone.0186638.g002
Non-communicable disease and care costs in HIV
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aged>50 in both countries by 2035, resulting in an increased NCD burden in this population.
The major drivers of NCD burdens will be hypertension, dyslipidaemia, diabetes and malig-
nancies. These shifts will have considerable implications for direct HIV care costs, with average
care costs attributable to NCD treatment expected to double in Italy and increase by 40% in
the USA. Evidence based approaches on effective prevention interventions and treatment pro-
tocols will be vital to mitigate this growing burden and offset improvements in HIV care and
quality of life achieved to date.
The issues of ageing with HIV are gaining momentum amongst global HIV stakeholders.
UNAIDS published its “Gap report” [18] in 2014 focusing on older HIV-positive population
and regional and national HIV guidelines are increasingly incorporating recommendations on
the management of NCDs in HIV care [19–21]. Recently published guidelines in Italy [19],
current European AIDS Clinical Society [20] and USA [21] guidelines for example provide
guidance on management of NCDs in HIV-positive patients. As HIV care focus shifts from
treatment of opportunistic infections to the long term prevention, screening and treatment of
NCDs, particular attention needs to be given to optimal ART choice [3], management of drug-
Fig 3. The predicted change in non-communicable disease burden. A. The number of HIV-positive patients on antiretroviral
therapy with 0,1, 2 or 3 and more non-communicable diseases between 2015 and 2035 in Italy and USA. Note: the two graphs are
not on the same axis. B. The predicted co-morbidities profiles amongst HIV-positive patients on antiretroviral therapy in 2035 based
on a cross-section of 100 patients (each square represents one patient) for Italy and the USA. Abbreviations: Cardiovascular disease
(CVD), Chronic kidney disease (CKD), Moderate CVD (dyslipidemia and/or hypertension) and Severe CVD (MI or stroke); United
States of America (USA).
https://doi.org/10.1371/journal.pone.0186638.g003
Non-communicable disease and care costs in HIV
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interactions between ART and NCD medication, and adherence in light of increasing poly-
pharmacy [22]. The need for multi-disciplinary patient management with a focus on geriatric
principals, personalised treatment protocols, and prevention interventions (including guid-
ance on modifiable risk factors such as smoking, diet, exercise and other risk factors) will also
be vital.
Practical application of care guidelines is an important issue; and can only become a reality
when there is suitable training in place for health care providers. The evolving care require-
ment raises the issue of accountability; with patients receiving treatment for HIV and NCDs,
the majority of care may fall on primary care physicians or HIV-specialists, although in some
countries patients are already referred to general population specialists for specific NCD care.
Integrated training is one possible avenue whereby HIV specialists are provided additional
extensive training in geriatric medicine [23]. Yet little is known about which prevention inter-
ventions work best in the ageing HIV-positive population where there are also barriers to the
prevention of NCDs such as smoking cessation [24].
The trends observed in Italy and the USA are similar to forecasts made for The Netherlands
[9]. Smit et al found that by 2030 70% of HIV-positive patients on ART will be aged>50 (our
forecasts show 76% for Italy and 74% for USA by 2035 and 65% for Italy and 69% for USA by
2030), and that 84% will be diagnosed withNCD (our forecasts show 89% for both Italy and
the USA by 2035 and 85% for Italy and 88% in the USA by 2030). As with Italy and the USA,
this NCD burden will be driven mainly by CVD and diabetes. The burden of multi-morbidity
(>3 NCDs) is forecasted to be higher in the USA compared to Italy and The Netherlands (28%
in The Netherlands, 29% in Italy and 44% in the USA in 2030). Our current estimates of mean
age are also in line with national reports, with the USA reporting that around 42% of patients
are aged >50 (39% in our study) [25] and Italy reporting 29% (30% in our study) [12].
The models capture the major age-related NCDs, including their common physiological
pathways. They were parameterized using large and nationally representative cohort data
[15,26], and scaled to national level using national HIV surveillance data. Out-of-sample
checks ensured that the model results were robust in the short-term (Section 6 in S1 File). Cost
Fig 4. Percentage contribution of HIV and NCD treatment costs to overall costs of care of HIV-positive patients on
antiretroviral therapy in 2015 and 2035 in A. Italy and B. the USA. Abbreviations: Chronic kidney disease (CKD), Myocardial
infraction (MI).
https://doi.org/10.1371/journal.pone.0186638.g004
Non-communicable disease and care costs in HIV
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estimates of NCD care and treatment were based on proven methodology in Italy [16,17] and
standard health economic method using robust insurance data from the USA.
The model is limited by the fact that it assumes homogenous national co-morbidity risk
and burden in Italy and the USA. In the absence of national data on NCDs, estimates from
available cohorts were assumed to directly translated to national level. As ICONA enrolls only
ART-naïve patients, the average patient is likely to have less advanced disease than a typical
HIV-positive patient in Italy. Although a recent study showed that recently enrolled patients
were representative of Italian HIV-positive people in the European Surveillance system,
ICONA may slightly over-represent men who have sex with men and underrepresent people
reporting other mode of transmission, older people and those with low CD4 counts [26]. US
data were generally representative of an insured US population in terms of sex, race, age and
geographical distribution [15]. However, they likely represented patients with the best access
to health care and not reflect patients who rely on public insurance, such as Managed or Fee-
for-Service Medicaid, or those with limited or no health insurance. Extrapolation to poorer or
under-served, vulnerable populations need to be made with caution; who are known to be
more complex with respect to comorbidity, in part due to social or behavioral factors [27]. Fur-
ther, as entry into the data requires interactions with the health care system, they may have
had a small bias towards patients with greater consumption of health care resources. This may
result in an underestimation of both the burden of NCDs and health care needs.
Furthermore, the model focuses on simulating HIV-positive patients in care and on ART
and does not include all the NCDs that can affect these population; in particular, undiagnosed
NCDs and neurocognitive or central nervous conditions which are poorly collected in HIV
cohorts. This make the results of this study a conservative estimate of the true NCD burden
affecting HIV-positive people in Italy and the USA in the next 20 years. The prevalence of MI,
stroke and malignancy refers to ever having been diagnosed with these NCDs. The model does
not account for recurrent MI, strokes or malignancies nor costs associated with recurrent
events. Instead it is assumed that treatment last on average one year following the incidence of
these three NCDs. As further robust age-specific data on these NCDs becomes available the
model can be expanded. Estimates for annual HIV-incidence also do not take into account the
lag that can occur between becoming newly infected and initiating treatment. Furthermore,
the model does not account for the introduction of “test and offer” ART policies which may
reduce HIV and NCD incidence [3]. Nor does the model account for migration (which may
impact the burden of both HIV and NCDs, as well as the care cascade [28]) or the introduction
of long-acting antiretroviral drugs (which have demonstrated good tolerability in existing tri-
als, on drug-interactions [29]). The cost analysis for Italy are limited by the fact that cost esti-
mates from one Italian region are extrapolated nationally, that costs for MI and strokes in Italy
are based on treatment costs for a wider range of chronic CVD events excluding not MI and
strokes, that frequently recovery costs in HIV-positive patients are attributed to HIV not
NCDs and that compliance to NCDs treatments in Italy is likely lower than recommended
protocols, (resulting in a likely underestimation of true necessary treatment costs) [16]. This
lower compliance is likely due to the lack of electronic prescription system for medication for
chronic diseases in Italy, meaning patients need to visit their physicians every month or two to
renew prescription, affecting secondary adherence.
Finally, it is difficult to make direct comparisons between both settings due to the inherent
differences in the populations, healthcare systems (mainly private in the USA and public in
Italy), data sources (USA from privately insured patients, Italy ART-naïve patients) and health
care systems cost differences. However, the results provide a first robust country-specific
insight into the future HIV care challenges in both countries.
Non-communicable disease and care costs in HIV
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Conclusions
Italian and US HIV-positive populations are ageing, increasing the NCD burden related direct
treatment costs. To ensure the highest level of care is maintained for these populations, multi-
disciplinary patient management and enhanced collaboration and linkage between HIV spe-
cialists, geriatric medicine and primary care must be developed. Further predictions must be
made for populations where future co-morbidity estimates (and consequent care strategies)
cannot be extended to, such as sub-Saharan Africa.
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